Coherus Oncology, Inc. (CHRS) has a consensus analyst rating of Buy, based on 16 analysts covering the stock. Of those, 13 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for CHRS is $6.02, representing a +220.2% upside from the current price of $1.88. Price targets range from a low of $1.05 to a high of $11.00.
